Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,996
datasets available to search
ShareScore release 0.7.1
Dataset results
2,996 results for “COPD”
Data inputs and results from AI-supported title and abstract screening "Lack of evidence regarding markers identifying acute heart failure in patients with COPD: an AI-supported systematic review"
<p>These comma-separated data files were used to conduct the AI supported screening of [Lack of Evidence Regarding Markers Identifying Acute Heart Failure in Patients with COPD: An AI-supported Systematic Review (working title)], following the methodology described in the publication (URL/doi to be uploaded).</p> <p>These files provide insight into the AI-supported screening process and the choices made by the human reviewer.</p>
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation
ClinicalTrials.gov study NCT03930732. IPD Sharing: YES. Countries: 24. Publications: 5.
Capnography-Assisted Learned Monitored (CALM) Breathing Therapy for COPD
ClinicalTrials.gov study NCT04786184. IPD Sharing: YES. Countries: 1. Publications: 1.
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
ClinicalTrials.gov study NCT04921332. IPD Sharing: YES. Countries: 1. Publications: 3.
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
ClinicalTrials.gov study NCT04072887. IPD Sharing: YES. Countries: 26. Publications: 1.
Efficacy and Safety Study of QVA149 in COPD Patients
ClinicalTrials.gov study NCT02487446. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
INtervention Study In overweiGHT Patients With COPD
ClinicalTrials.gov study NCT02634268. IPD Sharing: YES. Countries: 1. Publications: 1.
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
ClinicalTrials.gov study NCT04456673. IPD Sharing: YES. Countries: 29. Publications: 2.
Broccoli Sprout Extracts Trial to See if NRF2 is Enhanced by Sulforaphane Treatment in Patients With COPD
ClinicalTrials.gov study NCT01335971. IPD Sharing: YES. Countries: 1. Publications: 2.
Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov study NCT03546907. IPD Sharing: YES. Countries: 10. Publications: 1.
The airway microbiota and exacerbations of COPD
<p><span><span><span><span><span><span><span><span><span><span><span>Aim: To investigate whether the compositionality of the lower airway microbiota predicts later exacerbation risk in persons with COPD in a cohort study.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span>Materials and methods: We collected lower airways microbiota samples by bronchoalveolar lavage and protected specimen brushes, and oral wash samples from 122 participants with COPD. Bacterial DNA was extracted from all samples, before we sequenced the V3-V4 region of the 16S RNA gene. The frequency of moderate and severe COPD exacerbations was surveyed in telephone interviews and in a follow-up visit. Compositional taxonomy and alpha and beta diversity were compared between participants with and without later exacerbations. </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span>Results: The four most abundant phyla were <i>Firmicutes</i>, <i>Bacteroidetes</i>, <i>Proteobacteria</i> and <i>Fusobacteria</i> in both groups, and the four most abundant genera were <i>Streptococcus</i>, <i>Veillonella</i>, <i>Prevotella</i> and <i>Gemella</i>. The relative abundances of different taxa showed a large variation between samples and individuals, and no statistically significant difference of either compositional taxonomy, or alpha or beta diversity could be found between participants with and without COPD exacerbations within follow-up. </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span>Conclusion: The findings from the current study, indicate that individual differences in the lower airway microbiota in persons with COPD far outweigh group differences between frequent and non-frequent COPD exacerbators, and that the compositionality of the microbiota is so complex as to present large challenges for use as a biomarker of later exacerbations. </span></span></span></span></span></span></span></span></span></span></span></p>
HHIP's Dynamic Role in Epithelial Wound Healing Reveals a Potential Mechanism of COPD Susceptibility - Supplementary File 2
<p>This is a collection of files necessary to reproduce a subset of the results discussed in the manuscript entilted <em>HHIP’s Dynamic Role in Epithelial Wound Healing Reveals a Potential Mechanism of COPD Susceptibility</em> by Deritei et al. (currently available on bioRxiv: <a href="https://www.biorxiv.org/content/10.1101/2024.09.05.611545v2.abstract">https://www.biorxiv.org/content/10.1101/2024.09.05.611545v2.abstract</a>).</p> <p>Files are read by the <em>dynmod</em> software (<a href="https://github.com/Ravasz-Regan-Group/dynmod">https://github.com/Ravasz-Regan-Group/dynmod</a>) to simulate the large Boolean model’s behaviors. These include the model in .dmms format (as well as .BooleanNet and .SBML formats, namely COPD_EMT_CellCycle_Apoptosis.dmms, COPD_EMT_CellCycle_Apoptosis_Fine.booleannet, the “in silico protocol” files for reproducing all figures (COPD_Figures.vex), re-running the validation experiments (Validation_Table_COPD_EMT_CellCycle_Apoptosis.vex) and running a python script that performs all validation statistical tests, generating a results list and regenerating Supplementary File 3 (Large Model Validation Script.py, ST5 - Large model validation.csv).</p> <p>The _EXP folder contains exported figures necessary for generating the main manuscript Figure 4 and Supplementary Figures 3,4 and 5.</p> <p> </p>
Chlorhexidine oral rinses for symptomatic COPD: a randomized, blind, placebo-controlled preliminary study
<p>Background: Chlorhexidine oral rinses decrease ventilator-associated pneumonia but its effect on COPD is unknown.</p> <p>Research Question: Will a preliminary study of the effect of twice-daily chlorhexidine oral rinses on oral and lung microbiota biomass and respiratory symptoms, compared to placebo, support the conduct of a larger clinical trial?</p> <p>Study Design and Methods: Participants aged 40-85 with COPD and chronic respiratory symptoms were randomized 1:1 to twice-daily 0.12% chlorhexidine oral rinses vs. placebo.</p> <p>Results: Forty-four participants were recruited between September 8, 2014 and May 30, 2019. Our primary outcome was a change in oral and sputum microbiota biomass during the study as assessed by 16S rRNA copy numbers. Neither the oral microbiota nor the sputum microbiota biomass decreased significantly in those using chlorhexidine compared with placebo (oral microbiota mean log10 difference [SE] = -0.103 [0.23], 95% CI: -0.59, 0.38, p=0.665; sputum microbiota 0.80 [0.46], 95% CI: -0.15, 1.75, p=0.096). Chlorhexidine decreased both oral and sputum microbiota alpha (Shannon) diversity (linear regression estimate [SE] oral: -0.349 [0.091], p=0.001; sputum -0.622 [0.169], p=0.001). Chlorhexidine use did not decrease systemic inflammatory markers compared to placebo (CRP [chlorhexidine 1.8 ± 7.5 vs. placebo 0.4 ± 6.8, p=0.467], fibrinogen [22.5 ± 77.8 vs. 10.0 ± 77.0, p=0.406], or leukocytes [0.2 ± 1.8 vs. 0.5 ± 1.8, p=0.560]). Chlorhexidine use decreased St. George's Respiratory Questionnaire scores compared to placebo (chlorhexidine -4.7 ± 8.0 vs. placebo 1.7 ± 8.9, p=0.032).</p> <p>Interpretation: We did not detect a significant difference in microbiota biomass due to chlorhexidine use. Chlorhexidine decreased oral and sputum microbiota alpha diversity and improved respiratory health-related quality of life compared to placebo. Our results support the performance of a larger clinical trial.</p>
The oropharyngeal microbiome of COPD patients and controls in a livestock dense area
<p>This ready to load <strong>phyloseq</strong> R S4 object contains the ASV table, taxonomy table and sample metadata. This dataset was build using the DaDa2 (version 1.6.0) and phyloseq (version 1.223) R packages using our raw MiSeq PE300 sequencing data deposited at NCBI-SRA under BioProject: PRJNA810336. Additional metadata is available upon request. </p> <p><strong>Study</strong></p> <p>Air pollution from livestock farms is a known respiratory health risk for patients with chronic obstructive pulmonary disease (COPD). We hypothesize that air pollutants could affect respiratory health through modulation of the airway microbiome. Therefore, we studied determinants of the oropharyngeal microbiota (OPM) composition of COPD patients and controls in a livestock-dense area.</p> <p>Oropharyngeal swabs were collected from 99 community-based (mostly mild) COPD cases and 184 controls (baseline), and after 6 and 12 weeks. Participants were non-smokers or former smokers, Annual average livestock-related outdoor air pollution at the home address was predicted using dispersion modeling. OPM composition was analyzed using 16S rRNA-based sequencing in all baseline samples and 6-week and 12-week repeated samples of 20 randomly selected subjects (n=323 samples).</p> <p>Case-control status was not associated with community structure while correcting for known confounders (multivariate PERMANOVA p>0.05). However, members of the genus <em>Streptococcus</em> were more abundant in the COPD group (Benjamini-Hochberg adjusted p<0.01). Both farm-emitted endotoxin and PM<sub>10 </sub>levels were associated with increased richness in COPD patients (p<0.05). Procrustes analysis showed a moderate correlation between ordinations (Principal coordinates analysis of Bray-Curtis dissimilarity) of 20 subjects analyzed at 0, 6, and 12 weeks (r=0.52 to 0.66; p<0.05) indicating that the OPM is relatively stable over a 12 week period and that a single sample sufficiently represents the OPM.</p> <p>Results show modest differences in OPM of community-based COPD patients compared to controls. Livestock-related air pollution was associated with OPM diversity of COPD patients. </p>
Factors associated with coronary heart disease in COPD patients and controls
<p><strong><span>Background</span></strong></p> <p><span>COPD and coronary heart disease (CHD) frequently co-occur, yet which COPD phenotypes are most prone to CHD is poorly understood. </span><span>The aim of this study was to see whether COPD patients did have a true higher risk for CHD than subjects without COPD, and to examine a range of potential factors associated with CHD in COPD patients and controls</span></p> <p><strong><span>Methods</span></strong></p> <p><span>347 COPD patients and 428 non-COPD controls, were invited for coronary computed tomography angiography (CCTA) and pulmonary CT. Arterial blood gas, bioelectrical impedance and lung function was measured, and a detailed medical history taken. The CCTA was evaluated for significant coronary stenosis and calcium score (CaSc), and emphysema defined as >10% of total area <-950 Hounsfield units. </span></p> <p><strong><span>Results</span></strong></p> <p><span>12.6% of the COPD patients and 5.7% of the controls had coronary stenosis (p<0.01), whereas 55.9% of the COPD patients had a CaSc>100 compared to 31.6% of the controls (p<0.01). In a multivariable model adjusting for sex, age, body composition, pack-years, CRP, cholesterol/blood pressure lowering medication use and diabetes mellitus, the OR (95% CI) for having significant stenosis was 1.80 (0.86-3.78) in COPD patients compared with controls. In a similar model, the OR (95% CI) for having CaSc>100 was 1.68 (1.12-2.53) in COPD patients compared with controls. Examining the risk of significant stenosis and CaSc>100 among COPD patients, no variable was associated with significant stenosis, whereas male sex [OR 2.85 (1.56-5.21)], age [OR 3.74 (2.42-5.77)], statin use [OR 2.23 (1.23-4.50)] were associated with CaSc>100, after adjusting for body composition, pack-years, C-reactive protein, use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), diabetes, emphysema score, GOLD category, exacerbation frequency, eosinophilia, and hypoxemia.</span></p> <p><strong><span>Conclusion</span></strong></p> <p><span>COPD patients were more likely to have CHD, but neither emphysema score, lung function, exacerbation frequency, nor hypoxemia predicted presence of either coronary stenosis or CaSc>100. </span></p>
data set regarding to project- Malnutrition, sarcopenia and malnutrition-sarcopenia syndrome in Older Adults with COPD
<p><strong>data set regarding to project- Malnutrition, sarcopenia and malnutrition-sarcopenia syndrome in Older Adults with COPD</strong></p>
From Good Science to Good Practice: An Implementation Evaluation of a Home-based Exercise Intervention for COPD Patients
<p>With this study we aimed to comprehensively evaluate the implementation of the home-based HOMEX exercise program in the course of an RCT and the subsequent months, considering the perspective and experience of the involved persons and potential future providers. The results provided guidance to optimize the program and material and to ensure the programs’ long-term sustainability. We provide the following data:</p> <p>Data from patients</p> <ul> <li>Excel File <strong><em>Satisfaction_IG_HOMEX-1_T4.xlsx</em></strong> <ul> <li>Satisfaction questionnaire, 1-year follow-up, intervention group participants (n=53)</li> </ul> </li> <li>Word Files <ul> <li>Transcripts of interviews with 9 selected intervention group participants</li> </ul> </li> </ul> <p>Data from coaches:</p> <ul> <li>Excel File <strong><em>Coaches_Questionnaire_Satisfaction.xlsx</em></strong> <ul> <li>Satisfaction survey, after study end, 12 coaches</li> </ul> </li> </ul> <p> </p> <p><strong>Publication:</strong></p> <p>Cerini T, Kunz R, Dalla Lana K, Radtke T, Polhemus A, Puhan MA, Frei A. Evaluation of the Implementation of a Home-Based Exercise Training Program for People With COPD: A Mixed-Methods Study. <em>Frontiers in Rehabilitation Sciences</em> Front Rehabil Sci; 2021; 2: 743588 / DOI: <a href="https://doi.org/10.3389/fresc.2021.743588"> 10.3389/fresc.2021.743588 </a></p> <p> </p>
Epigenetic deregulation of IFN and WNT pathways in AT2 cells impairs alveolar regeneration (in COPD)
<h2>Data-sets</h2><p>RNAseq_CountTable.tsv: Raw count table from RNA-seq experiments</p><p>WGBS_MethylationTable.tsv: Total read coverage and number of methylated sites at CpG positions (reference genome: hg19) </p><h2>Abstract</h2><p>Chronic lung diseases, including chronic obstructive pulmonary disease (COPD), affect over 500 million people and are a leading cause of death worldwide. A common feature of both chronic and acute lung diseases is altered respiratory barrier integrity and impaired lung regeneration. We hypothesized that alveolar type 2 (AT2) cells, as alveolar epithelial progenitors, will carry molecular alterations that compromise alveolar regeneration in COPD. Sorted AT2 cells from ex-smokers with and without COPD at different disease stages were subjected to RNA sequencing and whole-genome bisulfite sequencing to generate unbiased transcriptome and DNA methylation maps of alveolar progenitors in the lung. Our analysis revealed genome-wide epigenetic changes in AT2 cells during COPD that were associated with global gene expression changes. Integrative data analysis uncovered a strong anti-correlation between gene expression and promoter methylation, suggesting that dysregulation of COPD-associated pathways in AT2 cells may be regulated by DNA methylation. Interferon (IFN) signaling was the top-upregulated pathway associated with the concomitant loss of promoter DNA methylation. Epigenetic regulation of the IFN pathway was validated in both global and targeted DNA demethylation assays in A549 cells. Notably, targeted DNA demethylation of IRF9 triggered upregulation of IFN signaling, mimicking the effects observed in COPD AT2 cells in the profiling data. Our findings suggest that COPD-triggered epigenetic alterations in AT2 cells impair internal regeneration programs in human lung parenchyma.</p>
Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices
ClinicalTrials.gov study NCT02596009. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.
ClinicalTrials.gov study NCT00496470. IPD Sharing: Not stated. Countries: 9. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.